CAS 212142-18-2

Vatalanib succinate

Description:

Vatalanib succinate, with the CAS number 212142-18-2, is a small molecule that functions primarily as a tyrosine kinase inhibitor. It is designed to target specific receptors involved in angiogenesis, particularly the vascular endothelial growth factor (VEGF) receptors, which play a crucial role in tumor growth and metastasis. This compound is characterized by its ability to inhibit tumor vascularization, thereby potentially limiting the growth of various cancers. Vatalanib succinate is typically administered in a pharmaceutical formulation, often as a salt to enhance its solubility and bioavailability. The substance exhibits a moderate to high affinity for its target receptors, which contributes to its therapeutic efficacy. Additionally, it is important to consider its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, which influence its overall effectiveness and safety profile in clinical settings. As with many targeted therapies, ongoing research continues to explore its potential applications and optimize its use in cancer treatment.

Formula: C₂₄H₂₁ClN₄O₄

InChI: InChI=1/C20H15ClN4.C4H6O4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14;5-3(6)1-2-4(7)8/h1-12H,13H2,(H,23,25);1-2H2,(H,5,6)(H,7,8)

InChI key: InChIKey=LLDWLPRYLVPDTG-UHFFFAOYSA-N

SMILES: N(C=1C2=C(C(CC=3C=CN=CC3)=NN1)C=CC=C2)C4=CC=C(Cl)C=C4.C(CC(O)=O)C(O)=O

Synonyms:

• 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, butanedioate (1:1)
• Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1)
• Cgp 79787D
• N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine butanedioate
• N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine butanedioate (1:1)
• Ptk 787
• Ptk 787/Zk 222584
• Ptk 787Zk22258
• Zk 222584
• N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine succinate
• N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine succinate
• VATALANIB SUCCINATE

Butanedioic acid, compd. withN-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1)OTHER CA INDEX NAMES:1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-,butanedioate (1:1)

CAS: 212142-18-2

Formula: C₂₄H₂₁ClN₄O₄

Purity: 99%

Color and Shape: Solid

Molecular weight: 464.9009

Ref: IN-DA00I42A

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine succinate

CAS: 212142-18-2

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine succinate

Purity: 99%

Molecular weight: 464.91g/mol

Ref: 54-OR1066799

Vatalanib Succinate

CAS: 212142-18-2

Formula: C₂₀H₁₅ClN₄·C₄H₆O₄

Purity: >98.0%(T)(HPLC)

Color and Shape: White to Light yellow to Light orange powder to crystal

Molecular weight: 464.91

Ref: 3B-V0198

Vatalanib succinate

CAS: 212142-18-2

Vatalanib succinate is a VEGFR, PDGFR-β, c-Kit, c-Fms, and aromatase inhibitor.

Formula: C₂₄H₂₁ClN₄O₄

Color and Shape: Solid

Molecular weight: 464.91

Ref: TM-T71897

Vatalanib succinate

CAS: 212142-18-2

Vatalanib succinate is a small molecule drug that inhibits the activity of the vascular endothelial growth factor receptor (VEGFR). Vatalanib succinate binds to the VEGFR and prevents it from binding to its ligands, such as stem cell factor. It has been shown to inhibit metastatic colorectal cancer in animal models. Vatalanib succinate also has biological effects on other cancer cells, including HL-60 cells and mcf-7 cells. The combination of vatalanib succinate with other compounds, such as colony-stimulating factors or toll-like receptor antagonists, may have synergistic effects.

Formula: C₂₄H₂₁ClN₄O₄

Purity: Min. 95%

Molecular weight: 464.9 g/mol

Ref: 3D-MIA14218